Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 25, 2007

Elusys Receives $12M from NIAID/BARDA for Anthrax Therapeutic

  • Elusys Therapeutics was awarded a contract for $12 million  to advance its late-stage anthrax therapeutic, Anthim. This project has been funded in whole or in part by the NIAID and the Biomedical Advanced Research and Development Authority (BARDA), of the Deparment of Health and Human Services.

    To date Elusys says that it has received more than $32 million from NIAID/BARDA and the DoD in support of Anthim and the company’s Heteropolymer Antibody™ technology.

    “Elusys is encouraged by the continued support from the U.S. Government and we look forward to extending our collaboration with NIAID/BARDA,” says Elizabeth Posillico, Ph.D., president and CEO of Elusys. “We are confident that Elusys has developed a highly effective and valuable anthrax therapeutic for procurement under Project BioShield for addition to the U.S. Government’s Strategic National Stockpile.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »